By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Oxford BioTherapeutics 

94a Milton Park

Abingdon  Oxon  OX14 4RY  United Kingdom
Phone: 44-0-1235-861770 Fax: 44-0-1235-861771


SEARCH JOBS


Industry
Biotechnology






Company News
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014 5:41:30 AM
Oxford BioTherapeutics And Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate As Second Clinical Development Candidate In $1 Billion Oncology Investment Alliance 10/2/2014 8:58:52 AM
Oxford BioTherapeutics Appoints Dr. Eugen Leo As Head Of Clinical Development 7/8/2014 10:44:07 AM
Oxford BioTherapeutics Appoints Dr Keith E Wilson As Chief Scientific Officer 6/18/2014 9:26:37 AM
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD To Its Board Of Directors 1/15/2014 8:00:19 AM
Oxford BioTherapeutics And Menarini Group Progress Enhanced Antibody For Acute Myeloid Leukemia As First Clinical Development Candidate In $1 Billion Oncology Investment Alliance 12/9/2013 7:57:38 AM
Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman 6/26/2013 6:26:13 AM
Oxford BioTherapeutics and Boehringer Ingelheim Corporation Enter Collaboration to Discover Novel Antibody Targets in Cancer 4/29/2013 9:49:15 AM
Menarini, Oxford BioTherapeutics Ink $1 Billion Cancer Pact; Partnership Will Develop Five Antibody-Based Anticancer Drugs 10/29/2012 9:50:05 AM
Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 5/2/2012 10:35:47 AM
12
//-->